“Whether products are available and affordable to the people who need them in these markets depends on the choices companies make when registering, pricing and distributing their products”
This month the Access to Medicine Index published an independent ranking of 20 of the world’s leading pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries.
The report examines registration and pricing practices for specific products and countries. A key finding is more companies are making progress in setting prices reflecting the socioeconomic context, with greater use of equitable pricing strategies.
Yet performance of the pharmaceutical industry continues to lag in some areas critical to improving access. For example, whilst companies are refining their pricing strategies to improve affordability of more products, they are applying them in few countries.
The Index highlights the significant potential for the industry to make medicines more accessible.